Condition: Urticaria Chronic · Sponsor: ARS Pharmaceuticals, Inc.
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
This description comes directly from the study's public registry record.
Osnat Ehrman, MSc · 952.334.5797 · osnate@pacificlinkconsulting.com
Always discuss trial participation with your own doctor first.
| Endeavor Health Clinical Trials Center | Glenview, Illinois, United States | Recruiting |
| Bernstein Clinical Research Center, LLC | Cincinnati, Ohio, United States | Recruiting |
| Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30 | Berlin, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06927999